Immunotherapy with or without low-intensity chemotherapy versus conventional chemotherapy as first-line treatment for newly diagnosed B-ALL patients fit for intensive chemotherapy: a propensity score-matched study - Scorecard - MDSpire

Immunotherapy with or without low-intensity chemotherapy versus conventional chemotherapy as first-line treatment for newly diagnosed B-ALL patients fit for intensive chemotherapy: a propensity score-matched study

  • By

  • Bingqian Huang

  • Yawen Wang

  • Yubin Li

  • Jiahui Mao

  • Ruixue Wang

  • Gaoyu Lv

  • Ming Hou

  • Yan Shi

  • June 18, 2026

  • 0 min

Share

Clinical Scorecard: Comparative Effectiveness of Immunotherapy with or without Low-Intensity Chemotherapy versus Standard Chemotherapy in First-Line Treatment for Newly Diagnosed B-ALL Patients Eligible for Intensive Chemotherapy: A Propensity Score-Matched Analysis

At a Glance

CategoryDetail
Condition
Key MechanismsImmunotherapy targeting CD19 and CD22 antigens to induce cytotoxic effects.
Target Population
Care Setting

Key Highlights

  • transfusion_insights

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Monitor MRD levels and infection rates during and after treatment.

      Risks

        Patient & Prescribing Data

        Include potential long-term outcomes and follow-up care recommendations.

        Clinical Best Practices

        • patient_education

        Related Resources & Content

        Original Source(s)

        Immunotherapy with or without low-intensity chemotherapy versus conventional chemotherapy as first-line treatment for newly diagnosed B-ALL patients fit for intensive chemotherapy: a propensity score-matched study

        • by Bingqian Huang, Yawen Wang, Yubin Li, Jiahui Mao, Ruixue Wang, Gaoyu Lv, Ming Hou, Yan Shi

        • June 18, 2026

        Related Content

        Editorial: Innovative strategies in overcoming glioblastoma: advancements in treatment and research

        2026 AACR Prostate Cancer Highlights

        The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026.

        • June 17, 2026

        • 1 min
        Hepatic metastasis of mucinous adenocarcinoma with neuroendocrine differentiation harboring a rare HER2 R678Q mutation: a case report and literature review